Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies (original) (raw)

• Keating MJ, Kantarjian H, Smith TL et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071–1080.
  Article CAS PubMed Google Scholar
• de Witte T, Suciu S, Verhoef G et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326–2331.
  Article CAS PubMed Google Scholar
• Germing U, Gattermann N, Strupp C et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983–992.
  Article CAS PubMed Google Scholar
• World Health Organization. Pathology and Genetics. Tumours of Hematopoietic and Lymphoid Tissues. World Health Organization: Geneva, 2001.
• Heaney ML, Golde DW . Myelodysplasia. N Engl J Med 1999; 340: 1649–1660.
  Article CAS PubMed Google Scholar
• Bortin MM, Truitt RL, Rimm AA, Bach FH . Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature 1979; 281: 490–491.
  Article CAS PubMed Google Scholar
• Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
  CAS PubMed Google Scholar
• Anderson JE, Gooley TA, Schoch G et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578–2585.
  CAS PubMed Google Scholar
• Biggs JC, Horowitz MM, Gale RP et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090–1093.
  CAS PubMed Google Scholar
• Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.
  CAS PubMed Google Scholar
• Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
  CAS PubMed Google Scholar
• Giralt S . Non-myeloablative stem cell transplantation in myeloid leukemias – The M.D. Anderson Cancer Center experience. In: Giralt S, Slavin S (eds.). Non-myeloablative Stem Cell Transplantation (NST). Darwin Scientific Publishing Limited: Oxfordshire, 2000; pp 59–72.
  Google Scholar
• Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.
  Article CAS PubMed Google Scholar
• Saito T, Kanda Y, Kami M et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8: 1014–1020.
  CAS PubMed Google Scholar
• Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
  CAS PubMed Google Scholar
• Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.
  CAS PubMed Google Scholar
• Kanda Y, Mineishi S, Saito T et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689–692.
  Article CAS PubMed Google Scholar
• Pizzo PA . Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323–1332.
  Article CAS PubMed Google Scholar
• Kanda Y, Mineishi S, Saito T et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 2002; 73: 568–572.
  Article CAS PubMed Google Scholar
• Thiede C, Florek M, Bornhauser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.
  Article CAS PubMed Google Scholar
• Bearman S, Appelbaum FR, Buckner C et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.
  Article CAS PubMed Google Scholar
• Cheson BD, Cassileth PA, Head DR et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819.
  Article CAS PubMed Google Scholar
• Bornhauser M, Thiede C, Schuler U et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000; 26: 119–125.
  Article CAS PubMed Google Scholar
• Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241.
  CAS PubMed Google Scholar
• Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61.
  Article CAS PubMed Google Scholar
• Grever M, Leiby J, Kraut E et al. A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin Oncol 1990; 17 (5 Suppl. 8): 39–48.
  CAS PubMed Google Scholar
• Piro LD, Carrera CJ, Carson DA, Beutler E . Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–1121.
  Article CAS PubMed Google Scholar
• Cheson BD, Vena DA, Foss FM, Sorensen JM . Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12: 2216–2228.
  Article CAS PubMed Google Scholar
• Antin JH, Ferrara JL . Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964–2968.
  CAS PubMed Google Scholar
• Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
  Article CAS PubMed Google Scholar
• Morishima Y, Morishita Y, Tanimoto M et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 1989; 74: 2252–2256.
  CAS PubMed Google Scholar
• Hiraoka A, Ohashi Y, Okamoto S et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181–185.
  Article CAS PubMed Google Scholar
• Martin P, Nash R, Sanders J et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1998; 21: 273–279.
  Article CAS PubMed Google Scholar
• Bunn D, Lea CK, Bevan DJ et al. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996; 45: 29–32.
  CAS PubMed Google Scholar
• Chopra R, Chakraverty R, Chakrabartu S et al. Non-myeloablative conditioning limits transplant related mortality in patients who have previously failed high dose treatment. Blood 2000; 96: 553a.
  Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.
  Article CAS PubMed Google Scholar
• Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599.
  Article CAS PubMed Google Scholar
• Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329.
  CAS PubMed Google Scholar
• Hamaki T, Kami M, Tanimoto T et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning (RIST) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Int J Hematol 2002; 76 (Suppl. 1): 16.
  Google Scholar
• Fujimaki K, Fujisawa S, Aotsuka N et al. Feasibility of early tapering and discontinuation of cyclosporine to intensify the graft-versus-leukemia effect in patients with advanced hematologic neoplasms. Rinsho Ketsueki 2001; 42: 680–684.
  CAS PubMed Google Scholar
• Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.
  Article CAS PubMed Google Scholar
• Oka Y, Tsuboi A, Elisseeva OA et al. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2002; 2: 45–54.
  Article CAS PubMed Google Scholar
• Fontaine P, Roy-Proulx G, Knafo L et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001; 7: 789–794.
  Article CAS PubMed Google Scholar